A Phase 1 Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

164 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-03-10

Study Completion Date

2024-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A randomised, blinded, parallel-controlled phase 1 clinical trial to evaluate the safety and preliminary immunogenicity of a COVID-19 mRNA vaccine in a healthy population aged 18 years and older, and to investigate immunisation doses.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A PhaseⅡ Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine

NCT06113731

SARS-CoV-2 Infection

RECRUITING PHASE2

A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Adults Aged 18 -59 Years.

NCT05354089

SARS-CoV-2

UNKNOWN PHASE1

A Phase I/II Study to Evaluate a SARS-CoV-2 mRNA Vaccine in Healthy Adults

NCT05903118

SARS-CoV-2

COMPLETED PHASE1/PHASE2

A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Participants Aged 18 Years or More

NCT05439824

SARS-CoV-2 Infection

UNKNOWN PHASE2

Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19)

NCT04352608

COVID-19

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The phase 1 clinical trial is conducted in a randomised, blinded, parallel-controlled design to assess the safety, immunogenicity and immune persistence. Subjects will be divided into two age groups (18-59 and ≧60 years of age), and within the groups, subjects will be subdivided into three dose groups (10 μg,30 μg and 60 μg). The immunisation procedure is divided into one-dose group and two-dose group (0, 28 days).

The total sample size is 164 subjects. 12 subjects will be assigned to each group according to different age, dose and immunisation procedure, respectively. In addition, 20 subjects (10 aged 18-59 years and 10 aged ≧60 years) will be enrolled as active control and vaccinated with 2 doses of inactivated Covid vaccine (Vero cell) (0, 28 days).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

SARS-CoV-2 Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

saline

Intervention Type BIOLOGICAL

COVID-19 Vaccine (Vero Cell) ,Inactivated

COVILO

Intervention Type BIOLOGICAL

COVID-19 mRNA Vaccine (ZSVG-02-O) 10 μg

Low-dose

Intervention Type BIOLOGICAL

COVID-19 mRNA Vaccine (ZSVG-02-O) 30 μg

Mid-dose

Intervention Type BIOLOGICAL

COVID-19 mRNA Vaccine (ZSVG-02-O) 60 μg

High-dose

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy male or female subjects aged ≥18 years of age;
2. Subjects who are in good physical condition as judged by the investigator based on medical history, physical examination and clinical laboratory tests;
3. Subjects who have not been previously vaccinated with a Covid-19 vaccine or who have received the last dose (total dose ≤ 3 doses) of a Covid-19 vaccine at least 6 months ago;
4. Subjects who have not been previously infected with Covid-19, or whose nucleic acid or antigen test has turned negative for more than 1 month after previous Covid-19 infection;
5. Subjects who have used effective contraception since 2 weeks prior to enrolment;
6. Subjects or their delegates are able to understand the study procedures, have provide written informed consent, and are able to comply with the requirements of the clinical study protocol.

Exclusion Criteria

1. Females of childbearing potential who have a positive pregnancy test, are pregnant, breastfeeding, or planning to become pregnant within 12 months; males: whose spouse is planning to become pregnant within 1 year;
2. History of epilepsy, convulsions or seizures, psychosis or family history of psychosis;
3. Subjects who were using antipyretic, analgesic or anti-allergic drugs within 3 days before enrolment;
4. Have a previous history of severe allergy to any medication or vaccination (e.g. acute allergic reaction, urticaria, skin eczema, dyspnoea, angioneurotic oedema, or abdominal pain) or allergy to known components of a Covid-19 vaccine;
5. Have a history of hospital-diagnosed thrombocytopenia or other coagulation disorders;
6. Have a history of hospital-diagnosed known immunological impairment or hypofunction;
7. Subjects who have received immunoenhancement or immunosuppressant therapy (continuous use by oral or infusion for more than 14 days) within 3 months, and whole blood, plasma, or immunoglobulin within 1 month;
8. Known or suspected concomitant serious diseases, including: respiratory diseases, acute infections or active chronic diseases, liver and kidney diseases, severe diabetes, malignant tumours, infectious or allergic skin diseases, cardiovascular disease, and HIV infection (with test report);
9. Subjects suffering from various acute diseases or in the acute exacerbation of chronic diseases within 3 days before vaccination;
10. Subjects with clinically significant abnormalities in blood biochemistry, blood routine, urine routine, coagulation function, thyroid function, and myocarditis-related indicators detected during the screening;
11. Received live attenuated vaccine within 1 month before vaccination;
12. Received inactivated vaccine within 14 days before vaccination;
13. Axillary temperature ≥37.3℃;
14. Who have participated in other clinical trials within 3 months prior to the first dose of vaccination or plan to participate in other clinical trials during the study period;
15. Other conditions that the investigator deems inappropriate for participation in this clinical trial.

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes